IBT
ALNY icon

International Biotechnology Trust’s Alnylam Pharmaceuticals ALNY Stock Holding History

International Biotechnology Trust’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$6.52M Sell
36,800
-44,800
-55% -$8.55M 2.2% 18
2023
Q2 		$15.5M Buy
81,600
+35,000
+75% +$6.94M 4.72% 7
2023
Q1 		$9.33M Buy
46,600
+8,600
+23% +$1.81M 2.6% 12
2022
Q4 		$9.02M Hold
38,000
– – 2.79% 11
2022
Q3 		$7.6M Buy
38,000
+32,458
+586% +$6.19M 2.44% 14
2022
Q2 		$38K Sell
5,542
-32,458
-85% -$4.6M 0.4% 50
2022
Q1 		$21.7M Sell
38,000
-90,000
-70% -$13.7M 4.9% 3
2021
Q4 		$21.7M Buy
128,000
+53,000
+71% +$9.85M 4.84% 3
2021
Q3 		$14.2M Sell
75,000
-74,000
-50% -$13.9M 3.42% 10
2021
Q2 		$25.2M Buy
149,000
+40,200
+37% +$5.89M 6.66% 2
2021
Q1 		$15.4M Buy
108,800
+72,500
+200% +$10.9M 4.06% 9
2020
Q4 		$4.72M Hold
36,300
– – 1.29% 21
2020
Q3 		$5.28M Hold
36,300
– – 1.7% 19
2020
Q2 		$5.37M Buy
36,300
+14,000
+63% +$1.89M 1.79% 20
2020
Q1 		$2.42M Sell
22,300
-21,000
-48% -$2.42M 1.11% 21
2019
Q4 		$4.99M Buy
43,300
+9,500
+28% +$947K 1.8% 20
2019
Q3 		$2.71M Hold
33,800
– – 1.25% 20
2019
Q2 		$2.45M Hold
33,800
– – 0.91% 29
2019
Q1 		$3.16M Hold
33,800
– – 1.17% 29
2018
Q4 		$1.94M Sell
33,800
-19,000
-36% -$1.46M 1.2% 24
2018
Q3 		$3.54M Buy
52,800
+16,000
+43% +$1.61M 1.68% 21
2018
Q2 		$3.62M Hold
36,800
– – 1.39% 24
2018
Q1 		$4.38M Hold
36,800
– – 1.71% 19
2017
Q4 		$4.67M Sell
36,800
-4,500
-11% -$565K 1.65% 22
2017
Q3 		$4.85M Buy
+41,300
New +$3.53M 1.89% 18

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

International Biotechnology Trust's ALNY Position: Q3 2023 in Review

International Biotechnology Trust reduced its Alnylam Pharmaceuticals (ALNY) stake by 55% in Q3 2023, selling an estimated $8.55M and leaving 36,800 shares worth $6.52M. The position accounts for 2.2% of the portfolio, ranked #18.

International Biotechnology Trust first reported a position in ALNY in Q3 2017 and has held it in 25 quarters since. The position peaked at $25.2M in Q2 2021. 453 funds tracked by Wall St. Rank hold ALNY as of Q3 2023.

  • International Biotechnology Trust held 36,800 shares of Alnylam Pharmaceuticals worth $6.52M as of Q3 2023.
  • International Biotechnology Trust sold 44,800 Alnylam Pharmaceuticals shares in Q3 2023, an estimated $8.55M.
  • Alnylam Pharmaceuticals made up 2.2% of International Biotechnology Trust's portfolio in Q3 2023, its #18 holding.
  • International Biotechnology Trust first reported a position in Alnylam Pharmaceuticals in Q3 2017 and has held it in 25 quarters since.
  • International Biotechnology Trust's Alnylam Pharmaceuticals position peaked at $25.2M in Q2 2021.
  • 453 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2023.

Based on International Biotechnology Trust's 13F filing for Q3 2023, filed 14 Nov 2023.